ATE291628T1 - Verfahren zur hemmung der aktivität von osteoprotegerin-liganden - Google Patents

Verfahren zur hemmung der aktivität von osteoprotegerin-liganden

Info

Publication number
ATE291628T1
ATE291628T1 AT99942778T AT99942778T ATE291628T1 AT E291628 T1 ATE291628 T1 AT E291628T1 AT 99942778 T AT99942778 T AT 99942778T AT 99942778 T AT99942778 T AT 99942778T AT E291628 T1 ATE291628 T1 AT E291628T1
Authority
AT
Austria
Prior art keywords
opgl
nucleic acids
osteoprotegerin
ligands
inhibiting
Prior art date
Application number
AT99942778T
Other languages
German (de)
English (en)
Inventor
Torben Halkier
Jesper Haaning
Original Assignee
Pharmexa As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmexa As filed Critical Pharmexa As
Application granted granted Critical
Publication of ATE291628T1 publication Critical patent/ATE291628T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)
AT99942778T 1998-09-15 1999-09-13 Verfahren zur hemmung der aktivität von osteoprotegerin-liganden ATE291628T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA199801164 1998-09-15
US10289698P 1998-10-02 1998-10-02
PCT/DK1999/000481 WO2000015807A1 (en) 1998-09-15 1999-09-13 Method for down-regulating osteoprotegerin ligand activity

Publications (1)

Publication Number Publication Date
ATE291628T1 true ATE291628T1 (de) 2005-04-15

Family

ID=26065320

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942778T ATE291628T1 (de) 1998-09-15 1999-09-13 Verfahren zur hemmung der aktivität von osteoprotegerin-liganden

Country Status (24)

Country Link
US (2) US6645500B1 (cg-RX-API-DMAC7.html)
EP (1) EP1114166B1 (cg-RX-API-DMAC7.html)
JP (1) JP2002525060A (cg-RX-API-DMAC7.html)
KR (1) KR100671036B1 (cg-RX-API-DMAC7.html)
CN (1) CN1318105A (cg-RX-API-DMAC7.html)
AT (1) ATE291628T1 (cg-RX-API-DMAC7.html)
AU (1) AU754971B2 (cg-RX-API-DMAC7.html)
CA (1) CA2343654A1 (cg-RX-API-DMAC7.html)
CZ (1) CZ2001789A3 (cg-RX-API-DMAC7.html)
DE (1) DE69924392T2 (cg-RX-API-DMAC7.html)
EE (1) EE200100149A (cg-RX-API-DMAC7.html)
ES (1) ES2239457T3 (cg-RX-API-DMAC7.html)
HK (1) HK1040261A1 (cg-RX-API-DMAC7.html)
HR (1) HRP20010188A2 (cg-RX-API-DMAC7.html)
HU (1) HUP0103578A3 (cg-RX-API-DMAC7.html)
ID (1) ID28386A (cg-RX-API-DMAC7.html)
IL (2) IL141588A0 (cg-RX-API-DMAC7.html)
NO (1) NO20011304L (cg-RX-API-DMAC7.html)
NZ (1) NZ510508A (cg-RX-API-DMAC7.html)
PL (1) PL196790B1 (cg-RX-API-DMAC7.html)
PT (1) PT1114166E (cg-RX-API-DMAC7.html)
SK (1) SK3062001A3 (cg-RX-API-DMAC7.html)
TR (1) TR200100737T2 (cg-RX-API-DMAC7.html)
WO (1) WO2000015807A1 (cg-RX-API-DMAC7.html)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) * 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity
GB9908263D0 (en) * 1999-04-13 1999-06-02 Binding Site The Limited Eliciting improved immune responses
WO2000067777A1 (en) * 1999-05-07 2000-11-16 Biofan Pty Ltd A method of prophylaxis and treatment and agents useful therefor
CA2647796A1 (en) * 1999-07-28 2001-02-08 The Trustees Of The University Of Pennsylvania Method of inhibiting osteoclast activity
US6673771B1 (en) 1999-07-28 2004-01-06 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclast activity
AU7615600A (en) * 1999-09-27 2001-04-30 Eli Lilly And Company Osteoclast differentiation factor regulatory region
AUPQ314799A0 (en) * 1999-09-29 1999-10-21 University Of Western Australia, The Bone cell factor
HRP20020721B1 (en) * 2000-02-21 2012-04-30 H. Lundbeck A/S Novel method for down-regulation of amyloid
WO2001062284A2 (en) * 2000-02-21 2001-08-30 Pharmexa A/S Novel method for down-regulation of amyloid
US20030103978A1 (en) * 2000-02-23 2003-06-05 Amgen Inc. Selective binding agents of osteoprotegerin binding protein
WO2001062932A1 (en) * 2000-02-23 2001-08-30 Amgen Inc. Antagonistic selective binding agents of osteoprotegerin binding protein
AU2001266604A1 (en) * 2000-05-26 2001-12-11 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
AU2001288342A1 (en) * 2000-08-21 2002-03-04 Smith Kline Beecham Corporation Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
WO2002024228A1 (fr) * 2000-09-21 2002-03-28 Center For Advanced Science And Technology Incubation, Ltd. Méthode de régulation de la formation d'ostéoclastes
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
CA2441538A1 (en) * 2001-03-22 2002-10-17 Barnes-Jewish Hospital Stimulation of osteogenesis using rank ligand fusion proteins
DE60235418D1 (de) 2001-04-03 2010-04-01 Nestle Sa Osteoprotegerin in Milch
TR201809678T4 (tr) * 2001-06-26 2018-07-23 Amgen Fremont Inc Opgl ye karşi antikorlar.
MY144532A (en) * 2001-08-20 2011-09-30 Lundbeck & Co As H Novel method for down-regulation of amyloid
US20030109444A1 (en) * 2001-10-12 2003-06-12 Jonathan Lam Bone anti-resorptive compounds
JP4336467B2 (ja) * 2001-10-15 2009-09-30 株式会社林原生物化学研究所 破骨細胞形成抑制因子の産生を調節し得る物質のスクリーニング方法
EP1560843A4 (en) * 2002-01-04 2006-09-06 Xencor Inc NEW VARIANTS OF RANKL PROTEIN
US7399829B2 (en) 2002-01-04 2008-07-15 Xencor, Inc. Variants of RANKL protein
US7381792B2 (en) 2002-01-04 2008-06-03 Xencor, Inc. Variants of RANKL protein
AU2003243139B2 (en) 2002-04-05 2007-06-21 Amgen Inc. Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US6921538B2 (en) * 2002-05-10 2005-07-26 Allergan, Inc. Therapeutic treatments for neuropsychiatric disorders
MXPA05006147A (es) 2002-12-10 2005-08-26 Schering Plough Ltd Ligando del activador del receptor de nf-kb de canino, y metodos para preparar y usar el mismo.
KR20070058426A (ko) * 2004-06-02 2007-06-08 사이토스 바이오테크놀로지 아게 비-인간 tnf-펩티드의 담체 콘쥬게이트의 의학적 용도
US20080107597A1 (en) * 2006-01-12 2008-05-08 Anaptys Biosciences, Inc. Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
WO2008088594A2 (en) * 2007-01-12 2008-07-24 Anaptysbio, Inc. Isolation of antibodies that cross-react and neutralize rankl orginating from multiple species
CN101434656B (zh) * 2007-11-16 2011-12-14 首都医科大学 Opg-hsp70融合蛋白的制备方法及用途
WO2009154770A2 (en) * 2008-06-18 2009-12-23 The Texas A & M University System Mesenchymal stem cells, compositions, and methods for treatment of cardiac tissue damage
WO2011128892A2 (en) * 2010-04-12 2011-10-20 Protea Vaccine Technologies Ltd. Modified forms of pneumococcal surface immunogenic protein b (psipb)
CN107286245B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 Pd-l1和pd-l2重组蛋白及其用途
CN107286244B (zh) * 2016-04-11 2021-10-08 北京普纳生物科技有限公司 抗免疫检查点pd-l1和pd-l2肿瘤疫苗
CN108498786A (zh) * 2018-02-13 2018-09-07 南昌大学第二附属医院 载骨保护素的缓释纳米粒及其制备方法和应用
KR102154637B1 (ko) * 2018-11-12 2020-09-10 조선대학교산학협력단 Rankl의 돌연변이체, 및 이를 포함하는 골다공증 예방 또는 치료용 약학 조성물
US20250304708A1 (en) * 2022-09-07 2025-10-02 The Regents Of The University Of California Treatment of cancer by blockade of osteoprotegerin
KR20250118303A (ko) * 2024-01-29 2025-08-06 주식회사 아크젠바이오사이온스 Rankl의 돌연변이체 및 이를 포함하는 백신 조성물

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1237764B (it) * 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
DE4496393T1 (de) 1993-08-27 1996-11-21 Dow Chemical Co Verfahren zur Trennung von Enantiomeren
EP0755444A4 (en) * 1994-04-01 1998-01-14 Univ Utah MOLECULAR CLONING AND EXPRESSION OF AN INDUCTIBLE PROTEASOME ACTIVATOR BY INTERFERON GAMMA
US6340459B1 (en) * 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US6369027B1 (en) * 1995-12-22 2002-04-09 Amgen Inc. Osteoprotegerin
PT1114864E (pt) * 1996-12-13 2008-10-08 Schering Corp Antigénios de superfície de células de mamífero, reagentes relacionados
ATE497001T1 (de) * 1996-12-23 2011-02-15 Immunex Corp Rezeptor aktivator von nf-kappa b, rezeptor is mitglied der tnf rezeptor superfamilie
US5843678A (en) * 1997-04-16 1998-12-01 Amgen Inc. Osteoprotegerin binding proteins
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
HRP20010188A2 (en) * 1998-09-15 2002-04-30 Pharmexa As Method for down-regulating osteoprotegerin ligand activity

Also Published As

Publication number Publication date
EE200100149A (et) 2002-08-15
NO20011304D0 (no) 2001-03-14
IL141588A (en) 2008-07-08
CN1318105A (zh) 2001-10-17
IL141588A0 (en) 2002-03-10
TR200100737T2 (tr) 2001-07-23
PT1114166E (pt) 2005-08-31
AU754971B2 (en) 2002-11-28
HRP20010188A2 (en) 2002-04-30
DE69924392D1 (de) 2005-04-28
DE69924392T2 (de) 2006-03-09
WO2000015807A1 (en) 2000-03-23
SK3062001A3 (en) 2002-02-05
EP1114166A1 (en) 2001-07-11
KR20010085807A (ko) 2001-09-07
CA2343654A1 (en) 2000-03-23
AU5617399A (en) 2000-04-03
KR100671036B1 (ko) 2007-01-18
PL346698A1 (en) 2002-02-25
HUP0103578A3 (en) 2005-11-28
CZ2001789A3 (cs) 2001-08-15
US20040115199A1 (en) 2004-06-17
ID28386A (id) 2001-05-17
EP1114166B1 (en) 2005-03-23
JP2002525060A (ja) 2002-08-13
HK1040261A1 (zh) 2002-05-31
NO20011304L (no) 2001-05-15
US6645500B1 (en) 2003-11-11
HUP0103578A2 (hu) 2002-01-28
ES2239457T3 (es) 2005-09-16
PL196790B1 (pl) 2008-01-31
NZ510508A (en) 2005-05-27

Similar Documents

Publication Publication Date Title
DE69924392D1 (de) Verfahren zur hemmung der aktivität von osteoprotegerin-liganden
WO2000075350A3 (en) Nucleic acid sequences encoding proteins involved in fatty acid beta-oxidation and methods of use
EP1162272A3 (en) Generation of immune responses to prostate-specific antigen (SPA)
DE69837274D1 (de) Verfahren zur verkapselung von nukleinsäuren in lipiddoppelschichten
DK288183D0 (da) Fremgangsmade til fremstilling af et oligonucleotidt terapeutisk middel
FI113969B (fi) Menetelmä CD40:n liukoisen ligandin valmistamiseksi, sitä koodaava nukleiinihappo ja sen käyttö
WO1999029865A3 (en) A protein belonging to the tnf superfamily, nucleic acids encoding same, and methods of use thereof
DE69732535D1 (de) Oligonucleotidzusammenstellung und verfahren zur regulierung der protein b7 expression
NO960309L (no) Agonister og antagonister for humaninterleukin-10
RU94046017A (ru) Нуклеиновые кислоты, вектор, клетка или трансгенный организм, синтетические полипептиды, способ получения синтетического пептида, вакцинная композиция, применение нуклеиновой кислоты, способ стимуляции иммунной реакции, олигосахарид
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
NO20015021L (no) Fremgangsmåte til å nedregulere IL-5 aktivitet
RU97106340A (ru) Днк, кодирующая папиломавирус типа 6а человека
WO1999047558A3 (en) T cell costimulatory proteins, sequences and uses thereof
WO1998018822A3 (en) Novel human lim proteins
WO1998025956A3 (en) Human GTP-binding proteins
YU19701A (sh) Postupak za regulisanje na niže osteoprotegerinske ligandne aktivnosti
ATE233321T1 (de) Verbesserungen in der herstellung von proteinen in wirtszellen
EP1541587A3 (en) Method for down-regulating osteoprotegerin ligand activity
DE69130117D1 (de) Methode und Zusammensetzungen zur Behandlung von bösartigen Entartungen, die in Zusammenhang mit einer Proteinkinase stehen
WO1998031805A3 (en) Human zinc binding proteins
WO1998018942A3 (en) Novel human rab proteins
WO1998036068A3 (en) Human p24 vesicle proteins
Rasmussen et al. Repeated electroconvulsive shock selectively increases the expression of the neuron specific enolase in piriform cortex
EA200501773A1 (ru) Детоксифицированный tnf и способ получения

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1114166

Country of ref document: EP

REN Ceased due to non-payment of the annual fee